Clinical Genomics taps Roy Davis for board of directors — 3 insights

Written by Eric Oliver | December 12, 2017 | Print  |

Roy Davis will join the board of directors for Clinical Genomics, a cancer diagnostic solutions company.

Here's what you should know:

1. Mr. Davis has 30-plus years of executive experience across the U.S., Europe and Japan.

2. He notably served Johnson & Johnson for 27 years, eventually becoming president of J&J Development. He most recently served on Cleveland Clinic's Innovations Advisory Board.

3. Clinical Genomics CEO Lawrence LaPointe, PhD, said, "We are pleased to welcome Roy as our newest Board Member. He brings a deep understanding of healthcare and commercial expertise to our team. We are very fortunate to have him by our side as we continue to carry out our mission. Roy will be an asset to our Board of Directors, and provide valuable counsel to the organization."

More articles on supply chain:
8 trends in pharmaceutical sales — 95.7% still through distributors
Microbot Medical names former Codman Neurosurgery president to board: 4 key points
Medline, ROi enter into strategic agreement: 4 key notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.